Access Biotechnology — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed5AM Ventures+6 more
BiotechWilmington, US
Valerie Morisset(Executive Officer)inErin Lavelle(Executive Officer)inRobert Azelby(Executive Officer, Director)James Bucher(Executive Officer)Leone Patterson(Director)
BoardAdam Rosenberg(Director)
Co-investorsManta Ray VenturesACORN BIOVENTURESRA Capital
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.
BiotechHealthtechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)
BoardMichael Gladstone(Director)inDerek DiRocco(Director)inJulie Papanek Grant(Director)inJohn Josey(Director)Daniel Becker(Director)
Co-investorsAtlas VentureCanaan PartnersRA CapitalThe Column Group
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.